RÉSUMÉ
Essentials Platelet reactivity is correlated with thrombotic risk after percutaneous coronary intervention (PCI). Hematocrit (HCT) is associated with platelet reactivity as measured with the VerifyNow P2Y12 assay. We tested a formula proposed to correct VerifyNow measurements for HCT in 978 PCI patients. Correcting platelet reactivity for HCT did not improve the prediction of thrombotic events after PCI. SUMMARY: Background High on-treatment platelet reactivity is predictive for the occurrence of atherothrombotic events following percutaneous coronary interventions (PCIs). A low hematocrit (HCT) value is associated with higher platelet reactivity values, expressed in P2Y12 reaction units (PRU), as measured with the VerifyNow P2Y12 assay. However, it is suggested that this is only an in vitro phenomenon. Objective To determine whether adjusting PRU for HCT improves the predictive value for thrombotic events following PCI. Material and methods The VerifyNow P2Y12 assay was performed in clopidogrel-treated patients undergoing non-urgent PCI included in a prospective cohort study. PRU values were corrected for HCT with a formula proposed in recent literature. Receiver operating characteristic (ROC) curves were made to determine the optimal cut-off values to predict the occurrence of the primary endpoint, a composite of all-cause death and non-fatal myocardial infarction, stent thrombosis and ischemic stroke, during 1 year of follow-up. The chi-squared test was performed to determine whether correcting PRU for HCT improved the prediction of the primary endpoint. Results A total of 978 patients were analyzed. A negative correlation between PRU and HCT was observed (R2 = 0.104). The optimal cut-off value for the corrected PRU was 215. ROC analyses showed that prediction of the primary endpoint did not differ for the corrected PRU (area under the curve, 0.61; sensitivity, 0.57; specificity, 0.64) and the uncorrected PRU (area under the curve, 0.61; sensitivity, 0.69; specificity, 0.53). Conclusion Correcting PRU for HCT does not improve the prediction of thrombotic events following PCI.
Sujet(s)
Hématocrite , Intervention coronarienne percutanée , Tests fonctionnels plaquettaires , Récepteurs purinergiques P2Y12/analyse , Sujet âgé , Aire sous la courbe , Plaquettes/effets des médicaments et des substances chimiques , Clopidogrel , Femelle , Études de suivi , Humains , Mâle , Adulte d'âge moyen , Agrégation plaquettaire/effets des médicaments et des substances chimiques , Antiagrégants plaquettaires/usage thérapeutique , Études prospectives , Courbe ROC , Récepteurs purinergiques P2Y12/métabolisme , Risque , Sensibilité et spécificité , Thrombose/sang , Thrombose/traitement médicamenteux , Ticlopidine/analogues et dérivés , Ticlopidine/usage thérapeutiqueRÉSUMÉ
Patients with chronic kidney disease (CKD) have an increased risk of cardiovascular disease. Previous studies have suggested that patients with CKD have less therapeutic benefit of antiplatelet therapy. However, the relation between renal function and platelet reactivity is still under debate. On-treatment platelet reactivity was determined in parallel by ADP- and AA-induced light transmittance aggregometry (LTA) and the VerifyNow® System (P2Y12 and Aspirin) in 988 patients on dual antiplatelet therapy, undergoing elective coronary stenting. Patients were divided into two groups according to the presence or absence of moderate/severe CKD (GFR<60 ml/min/1.73 m²). Furthermore, the incidence of all-cause death, non-fatal acute myocardial infarction, stent thrombosis and stroke at one-year was evaluated. Patients with CKD (n=180) had significantly higher platelet reactivity, regardless of the platelet function test used. Patients with CKD more frequently had high on-clopidogrel platelet reactivity (HCPR) and high on-aspirin platelet reactivity (HAPR) regardless of the platelet function test used. After adjustment for potential confounders, this was no longer significant. The event-rate was the highest in patients with both high on-treatment platelet reactivity (HPR) and CKD compared to those with neither high on-treatment platelet reactivity nor CKD. In conclusion, the magnitude of platelet reactivity as well as the incidence of HPR was higher in patients with CKD. However, since the incidence of HPR was similar after adjustment, a higher rate of co-morbidities in patients with CKD might be the major cause for this observation rather than CKD itself. CKD-patients with HCPR were at the highest risk of long-term cardiovascular events.
Sujet(s)
Plaquettes/effets des médicaments et des substances chimiques , Maladie des artères coronaires/thérapie , Rein/physiopathologie , Intervention coronarienne percutanée/instrumentation , Antiagrégants plaquettaires/usage thérapeutique , Agrégation plaquettaire/effets des médicaments et des substances chimiques , Insuffisance rénale chronique/physiopathologie , Endoprothèses , Sujet âgé , Sujet âgé de 80 ans ou plus , Plaquettes/métabolisme , Maladie des artères coronaires/sang , Maladie des artères coronaires/diagnostic , Maladie des artères coronaires/mortalité , Thrombose coronarienne/mortalité , Thrombose coronarienne/prévention et contrôle , Femelle , Hémorragie/induit chimiquement , Humains , Mâle , Adulte d'âge moyen , Infarctus du myocarde/mortalité , Infarctus du myocarde/prévention et contrôle , Intervention coronarienne percutanée/effets indésirables , Intervention coronarienne percutanée/mortalité , Antiagrégants plaquettaires/effets indésirables , Tests fonctionnels plaquettaires , Valeur prédictive des tests , Études prospectives , Insuffisance rénale chronique/sang , Insuffisance rénale chronique/diagnostic , Insuffisance rénale chronique/mortalité , Facteurs de risque , Indice de gravité de la maladie , Accident vasculaire cérébral/mortalité , Accident vasculaire cérébral/prévention et contrôle , Facteurs temps , Résultat thérapeutiqueRÉSUMÉ
AIM: The aim of this study was to compare the effects of 300 mg or 600 mg clopidogrel loading dose, prior to carotid artery stenting (CAS) on the number of transcranial Doppler (TCD)-detected microembolic signals (MES) and to investigate the relationship between the magnitude of platelet reactivity and MES. METHODS: In this prospective randomized, double-blind study, 35 consecutive asymptomatic patients (17.1% females), scheduled for CAS and cardiac surgery were included. The primary endpoint was the number of TCD-detected MES. The secondary endpoints were the absolute magnitude of on-treatment platelet reactivity and the adverse cerebral events. Negative binomial regression to find predictors for sum of single emboli, the student's t-test to assess the association between platelet function tests and randomized dose of 300 mg or 600 mg clopidogrel, and the R2 calculation for the assessment of the association between platelet function tests and embolic load, were used. RESULTS: No statistically significant difference in the number of TCD-detected MES, in the sum of all the single emboli or showers and platelet aggregation measurements between the two groups was observed (aggregometry: 21.7±18.3 versus 23±18%, P=0.8499 and 45.8±17.5 versus 46.5±14.5%, P=0.9003) (verifyNow P2Y12 assay: 231±93 PRU versus 222±86 PRU, P=0.7704). In one patient a transient ischemic attack occurred. CONCLUSION: A loading dose of 300 mg of clopidogrel in combination with aspirin is as effective as 600 mg of clopidogrel in achieving adequate platelet inhibition and preventing periprocedural events in asymptomatic patients undergoing CAS prior to cardiac surgery.
Sujet(s)
Procédures de chirurgie cardiaque , Sténose carotidienne/chirurgie , Endoprothèses à élution de substances , Embolie intracrânienne/prévention et contrôle , Accident ischémique transitoire/prévention et contrôle , Ticlopidine/analogues et dérivés , Échographie-doppler transcrânienne , Sujet âgé , Sténose carotidienne/complications , Sténose carotidienne/imagerie diagnostique , Clopidogrel , Relation dose-effet des médicaments , Méthode en double aveugle , Femelle , Études de suivi , Cardiopathies/chirurgie , Humains , Embolie intracrânienne/complications , Embolie intracrânienne/imagerie diagnostique , Accident ischémique transitoire/imagerie diagnostique , Accident ischémique transitoire/étiologie , Mâle , Antiagrégants plaquettaires/administration et posologie , Pronostic , Études prospectives , Ticlopidine/administration et posologieRÉSUMÉ
BACKGROUND: Previous studies have suggested that women do not accrue equal therapeutic benefit from antiplatelet medication as compared with men. The physiological mechanism and clinical implications behind this gender disparity have yet to be established. METHODS: On-treatment platelet reactivity was determined in 717 men and 234 women on dual antiplatelet therapy, undergoing elective coronary stent implantation. Platelet function testing was performed using arachidonic acid and adenosine diphosphate-induced light transmittance aggregometry (LTA) and the VerifyNow P2Y12 and Aspirin assays. Also the incidence of all-cause death, non-fatal acute myocardial infarction, stent thrombosis and ischaemic stroke was evaluated. RESULTS: Women had higher baseline platelet counts than men. Women exhibited a higher magnitude of on-aspirin platelet reactivity using LTA, but not using the VerifyNow Aspirin assay. The magnitude of on-clopidogrel platelet reactivity was significantly higher in women as compared with men with both tests used. The cut-off value to identify patients at risk as well as the incidence of clinical endpoints was similar between women and men (16/234[6.8%] vs. 62/717[8.6%], p = 0.38). CONCLUSION: Although the magnitude of platelet reactivity was higher in women, the absolute difference between genders was small and both the cut-off value to identify patients at risk and the incidence of the composite endpoint were similar between genders. Thus, it is unlikely that the difference in platelet reactivity accounts for a worse prognosis in women.
RÉSUMÉ
BACKGROUND: The carriage of CYP2C19*2 and the use of proton-pump inhibitors (PPIs) and calcium-channel blockers (CCBs) has been associated with the diminished efficacy of clopidogrel. However, previous studies have only assessed the isolated impact of these risk factors for clopidogrel poor response. OBJECTIVES: The aim of the present study was to investigate the impact of the combined presence of three risk factors for clopidogrel poor response, that is, the use of CCBs, PPIs and the carriage of CYP2C19*2, on on-treatment platelet reactivity and the occurrence of atherothrombotic events in 725 patients on dual antiplatelet therapy undergoing elective coronary stenting. METHODS: In a prospective, follow-up study, on-treatment platelet reactivity was quantified using ADP-induced light transmittance aggregometry (LTA) and the VerifyNow P2Y12 assay. The clinical study endpoint was the composite of all-cause mortality, myocardial infarction, stent thrombosis and stroke at 1 year after stenting. RESULTS: Patients with either one or more than one risk factor exhibited increased platelet reactivity (mean relative increase one risk factor: 11% and > 1 risk factor: 22%, respectively). Sixty-four events occurred during follow-up (8.8% of the study population). Patients with one risk factor for clopidogrel poor response did not have an increased risk of the composite endpoint. However, patients using both CCBs and PPIs and carriers of CYP2C19*2 who used CCBs had a statistically significant increased risk of the composite endpoint [hazard ratio(HR)(adj) 2.2 95% CI, 1.0-5.3, P = 0.044 and HR(adj) 3.3 95% CI, 1.1-9.8, P = 0.032, respectively]. CONCLUSIONS: The presence of more than one of the three investigated risk factors for clopidogrel poor response is associated with an increased risk of adverse cardiovascular events within 1 year after elective coronary stenting.
Sujet(s)
Angioplastie transluminale percutanée assistée par laser/effets indésirables , Aryl hydrocarbon hydroxylases/génétique , Inhibiteurs des canaux calciques/usage thérapeutique , Activation plaquettaire/effets des médicaments et des substances chimiques , Inhibiteurs de la pompe à protons/usage thérapeutique , Thrombose/prévention et contrôle , Sujet âgé , Inhibiteurs des canaux calciques/administration et posologie , Inhibiteurs des canaux calciques/pharmacologie , Clopidogrel , Cytochrome P-450 CYP2C19 , Interactions médicamenteuses , Association de médicaments , Femelle , Humains , Mâle , Adulte d'âge moyen , Antiagrégants plaquettaires/administration et posologie , Antiagrégants plaquettaires/pharmacologie , Antiagrégants plaquettaires/usage thérapeutique , Inhibiteurs de la pompe à protons/administration et posologie , Inhibiteurs de la pompe à protons/pharmacologie , Facteurs de risque , Thrombose/enzymologie , Ticlopidine/administration et posologie , Ticlopidine/analogues et dérivés , Ticlopidine/pharmacologie , Ticlopidine/usage thérapeutiqueRÉSUMÉ
BACKGROUND: The TRITON-TIMI 38 study has identified three subgroups of patients with a higher risk of bleeding during treatment with the thienopyridine prasugrel: patients with a history of stroke or transient ischaemic attack (TIA), patients ≥75 years and patients with a body weight <60 kg. However, the underlying pathobiology leading to this increased bleeding risk remains to be elucidated. The higher bleeding rate may be due to a stronger prasugrel-induced inhibition of platelet aggregation in these subgroups. The aim of the present study was to determine whether on-treatment platelet reactivity is lower in these risk subgroups as compared with other patients in a large cohort on the thienopyridine clopidogrel undergoing elective coronary stenting. METHODS: A total of 1069 consecutive patients were enrolled. On-clopidogrel platelet reactivity was measured in parallel by light transmittance aggregometry, the VerifyNow® P2Y12 assay and the PFA-100 collagen/ADP cartridge. RESULTS: Fourteen patients (1.5%) had a prior history of stroke or TIA, 138 patients (14.5%) were older than 75 years and 30 patients (3.2%) had a body weight <60 kg. Age ≥ 75 years and a history of stroke were independent predictors of a higher on-treatment platelet reactivity. In contrast, a body weight <60 kg was significantly associated with a lower on-treatment platelet reactivity. CONCLUSION: In two high-risk subgroups for bleeding, patients ≥ 75 years and patients with previous stroke, on-clopidogrel platelet reactivity is increased. In contrast, in patients with a low body weight, on-clopidogrel platelet reactivity is decreased, suggesting that a stronger response to a thienopyridine might only lead to more bleeds in patients with low body weight.
RÉSUMÉ
BACKGROUND: The pathophysiology of stent thrombosis (ST) has evolved from the identification of single causative factors to a complex multifactorial model. OBJECTIVES: The aim of the present study was to investigate whether patients with a history of ST exhibit heightened platelet reactivity to clopidogrel and aspirin. PATIENTS/METHODS: Pretreatment and on-treatment platelet reactivity to clopidogrel and aspirin, as well as dual antiplatelet therapy resistance, was determined in 84 patients with a history of definite ST (cases: 41 early ST; 43 late ST) and in 103 control patients with a previously implanted coronary stent but no ST after the index procedure. Platelet function was evaluated with optical aggregometry, the VerifyNow P2Y12 and aspirin assays, the PFA-100 Innovance P2Y* cartridge, the flow cytometric vasodilator-stimulated phosphoprotein assay and urine 11-dehydrothromboxane B(2) measurement before and after the administration of a 600-mg loading dose of clopidogrel and 100 mg of aspirin. The study was registered at ClinicalTrials.gov, number NCT01012544. RESULTS: Patients with a history of early ST clearly demonstrated higher on-clopidogrel platelet reactivity than controls. Patients with both early and late ST exhibited heightened on-aspirin platelet reactivity status, and dual antiplatelet therapy resistance was more frequent. CONCLUSIONS: Patients with a history of early ST exhibit a poor response to clopidogrel. Furthermore, both early and late ST are strongly and independently associated with heightened on-aspirin platelet reactivity, and dual antiplatelet therapy resistance is more frequent.
Sujet(s)
Acide acétylsalicylique/pharmacologie , Plaquettes/cytologie , Thrombose coronarienne/anatomopathologie , Ticlopidine/analogues et dérivés , Sujet âgé , Études cas-témoins , Clopidogrel , Femelle , Cytométrie en flux/méthodes , Humains , Mâle , Adulte d'âge moyen , Antiagrégants plaquettaires/pharmacologie , Tests fonctionnels plaquettaires , Endoprothèses , Ticlopidine/pharmacologie , Résultat thérapeutique , Vasodilatateurs/pharmacologieRÉSUMÉ
BACKGROUND: Early coronary stent thrombosis occurs most frequent after primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI). OBJECTIVES: To identify the specific predictors of, respectively, acute and subacute stent thrombosis in patients after primary PCI for STEMI. PATIENTS/METHODS: Consecutive STEMI patients with angiographically confirmed early stent thrombosis were enrolled and compared in a 2 : 1 ratio with a matched control group. Clinical outcome was collected up to 1 year. RESULTS: Of 5842 STEMI patients treated with primary PCI, 201 (3.5%) presented with a definite early stent thrombosis. Of these, 97 (1.7%) had acute stent thromboses and 104 (1.8%) had subacute stent thromboses. Postprocedurally discovered dissection, undersizing and smaller stent diameter were the strongest predictors for acute stent thrombosis. No glycoprotein IIb/IIIa therapy and the use of drug-eluting stents were also associated with acute stent thrombosis. Lack of clopidogrel therapy in the first 30 days after the index PCI was the strongest predictor for subacute stent thrombosis. Mortality rates at 1-year follow-up were lower for acute stent thrombosis than for subacute stent thrombosis (8.3% vs. 13.2%, P = 0.294). The incidence of definite recurrent stent thrombosis at 1-year follow up was significantly lower after a first definite acute stent thrombosis than after a first definite subacute stent thrombosis (6.4% vs. 19.3%, P = 0.007 at 1 year). CONCLUSIONS: The specific risk factors for, respectively, acute and subacute stent thrombosis after primary PCI vary greatly. Mortality rates are high for both categories of stent thrombosis. However, recurrent stent thrombosis occurs more frequently after subacute stent thrombosis.
Sujet(s)
Angioplastie coronaire par ballonnet/méthodes , Infarctus du myocarde/thérapie , Thrombose/complications , Thrombose/étiologie , Sujet âgé , Clopidogrel , Femelle , Humains , Incidence , Mâle , Adulte d'âge moyen , Infarctus du myocarde/épidémiologie , Pays-Bas , Antiagrégants plaquettaires/usage thérapeutique , Enregistrements , Facteurs de risque , Endoprothèses/effets indésirables , Thrombose/thérapie , Ticlopidine/analogues et dérivés , Ticlopidine/usage thérapeutique , Résultat thérapeutiqueSujet(s)
Angioplastie coronaire par ballonnet/méthodes , Plaquettes/cytologie , Numération des plaquettes/méthodes , Acide acétylsalicylique/administration et posologie , Clopidogrel , Études de cohortes , Humains , Ischémie , Odds ratio , Antiagrégants plaquettaires/usage thérapeutique , Études prospectives , Courbe ROC , Thrombose , Ticlopidine/administration et posologie , Ticlopidine/analogues et dérivésRÉSUMÉ
BACKGROUND: High on-aspirin platelet reactivity (HAPR) is associated with atherothrombotic events following percutaneous coronary intervention (PCI). The aim of the present study was to identify the platelet function test sensitive for platelet cyclooxygenase-1 inhibition that best predicts atherothrombotic events. METHODS AND RESULTS: Nine hundred and fifty-one consecutive patients on dual antiplatelet therapy undergoing elective PCI were enrolled. On-aspirin platelet reactivity was measured in parallel by arachidonic acid (AA)-induced light transmittance aggregometry (AA-induced LTA), the VerifyNow® Aspirin Assay (VerifyNow® Aspirin Assay), the arachidonic acid prestimulated IMPACT-R (IMPACT-R AA) and the PFA-100 collagen/epinephrine cartridge (PFA COL/EPI). Cut-offs for HAPR were established by receiver-operator characteristic curve analysis. At 1-year follow-up, the composite of all-cause death, non-fatal acute myocardial infarction, stent thrombosis and ischemic stroke occurred more frequently in patients with HAPR when assessed by LTA [10.1% vs. 6.0%, P=0.020 (n=925)] and VerifyNow(®) [13.3% vs. 5.9%, P=0.015 (n=422)]. The VerifyNow(®) ASA assay (AUC=0.78) and, to a lesser extent, AA-induced LTA (AUC=0.73) added significantly to a model consisting of clinical and procedural risk factors in predicting atherothrombotic events. In contrast, the IMPACT-R (n=791) and the PFA Collagen/Epinephrine (n=719) were unable to discriminate between patients with and without primary endpoint at 1-year follow-up. None of the platelet function tests was able to identify patients at risk for bleeding. CONCLUSIONS: AA-induced LTA and the VerifyNow(®) ASA test were able to identify aspirin-treated patients undergoing PCI with stenting at risk for atherothrombotic events. The VerifyNow(®) Aspirin Assay had the highest predictive accuracy. None of the tests was able to identify patients at higher risk of bleeding.
Sujet(s)
Acide acétylsalicylique/pharmacologie , Cyclooxygenase 1/composition chimique , Inhibiteurs des cyclooxygénases/pharmacologie , Thrombose/diagnostic , Sujet âgé , Angioplastie coronaire par ballonnet/méthodes , Femelle , Humains , Mâle , Adulte d'âge moyen , Infarctus du myocarde/étiologie , Tests fonctionnels plaquettaires , Études prospectives , Courbe ROC , Reproductibilité des résultats , Plan de recherche , Risque , Endoprothèses , Thrombose/prévention et contrôleRÉSUMÉ
BACKGROUND: Multiple platelet function tests claim to be P2Y12-pathway specific and capable of capturing the biological activity of clopidogrel. OBJECTIVES: The aim of the present study was to determine which platelet function test provides the best reflection of the in vivo plasma levels of the active metabolite of clopidogrel (AMC). PATIENTS/METHODS: Clopidogrel-naive patients scheduled for elective percutaneous coronary intervention (PCI) received a 600 mg loading dose of clopidogrel and 100 mg of aspirin. For pharmacokinetic analysis, blood was drawn at 0, 20, 40, 60, 90, 120, 180, 240 and 360 min after clopidogrel loading and peak plasma concentrations (C(max)) of the AMC were quantified with liquid chromatography-tandem mass spectrometry (LC-MS/MS). Platelet function testing was performed at baseline and 360 min after the clopidogrel loading. RESULTS: The VASP-assay, the VerifyNow P2Y12-assay and 20 micromol L(-1) adenosine diphosphate (ADP)-induced light transmittance aggregometry (LTA) showed strong correlations with C(max) of the AMC (VASP: R(2) = 0.56, P < 0.001; VerifyNow platelet reactivity units (PRU): R(2) = 0.48, P < 0.001; VerifyNow %inhibition: R(2) = 0.59, P < 0.001; 20 micromol L(-1) ADP-induced LTA: R(2) = 0.47, P < 0.001). Agreement with C(max) of the AMC was less evident for 5 micromol L(-1) ADP-induced LTA or whole blood aggregometry (WBA), whereas the IMPACT-R ADP test did not show any correlation with plasma levels of the AMC. CONCLUSION: The flow cytometric VASP-assay, the VerifyNow P2Y12 assay and, although to a lesser extent, 20 micromol L(-1) ADP-induced LTA correlate best with the maximal plasma level of the AMC, suggesting these may be the preferred platelet function tests for monitoring the responsiveness to clopidogrel.